{
  "id": "parkinsons-psychosis",
  "title": "Parkinson's Disease — Psychosis",
  "version": "1.0",
  "icd10": [
    "** F06.0 (Psychotic disorder due to known physiological condition with hallucinations)",
    "F06.2 (Psychotic disorder due to known physiological condition with delusions)",
    "G20.A1 (Parkinson's disease without dyskinesia",
    "without fluctuations)",
    "G20.C (Parkinsonism",
    "unspecified)",
    "F03.90 (Dementia",
    "unspecified",
    "without behavioral disturbance)"
  ],
  "scope": "** Evaluation and management of psychosis in the setting of Parkinson's disease. Covers the full spectrum from minor visual hallucinations (passage hallucinations, presence hallucinations) to formed visual hallucinations, delusions (paranoid, jealousy), and delirium. Includes medication-induced psychosis, PD dementia-related psychosis, and intercurrent medical causes. Addresses the critical tension between treating psychosis (requires dopamine reduction) and maintaining motor function (requires dopamine). Applies to ED (acute psychosis), inpatient (severe, disruptive), and outpatient (chronic management) settings.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "— Core Labs (Order for All Patients)": [
        {
          "item": "CBC with differential",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Infection screen (UTI, pneumonia — most common delirium triggers)"
        },
        {
          "item": "BMP (Na, K, Cl, CO₂, BUN, Cr, glucose)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Metabolic derangements (hyponatremia, uremia, hypoglycemia) as cause of altered mental status"
        },
        {
          "item": "Urinalysis with culture",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "UTI — most common precipitant of delirium and acute psychotic worsening in elderly PD patients"
        },
        {
          "item": "TSH",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Hypothyroidism or hyperthyroidism — exacerbates cognitive symptoms"
        },
        {
          "item": "Vitamin B12",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Deficiency contributes to cognitive decline and psychiatric symptoms"
        },
        {
          "item": "Liver function tests (CMP)",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Hepatic encephalopathy; drug metabolism assessment (many PD meds hepatically cleared)"
        },
        {
          "item": "Blood cultures (if febrile)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-",
          "rationale": "Sepsis — common cause of acute psychosis in elderly"
        }
      ],
      "— Extended Labs (Order When Clinically Indicated)": [
        {
          "item": "Urine drug screen",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-",
          "rationale": "If substance use suspected; may detect unexpected medications"
        },
        {
          "item": "Medication levels (if applicable)",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Amantadine, lithium, anticonvulsant levels — toxicity can cause psychosis"
        },
        {
          "item": "Ammonia level",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "-",
          "rationale": "Hepatic encephalopathy if liver disease suspected"
        },
        {
          "item": "RPR/VDRL",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Neurosyphilis — treatable cause of psychosis in appropriate clinical context"
        },
        {
          "item": "HIV testing",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "If risk factors present — HIV-associated neurocognitive disorder"
        },
        {
          "item": "Cortisol (AM)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Adrenal insufficiency — especially if on chronic steroids"
        }
      ],
      "— Rare/Specialized Labs": [
        {
          "item": "Autoimmune encephalitis panel",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "If atypical course, rapid onset, or young patient — anti-NMDAR, LGI1, CASPR2 antibodies"
        },
        {
          "item": "Paraneoplastic antibody panel",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "If subacute onset, associated neurologic findings suggesting paraneoplastic process"
        },
        {
          "item": "CSF analysis (cell count, protein, glucose, cytology)",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "-",
          "rationale": "Only if infection or autoimmune encephalitis is on differential — not routine for PDP"
        }
      ]
    },
    "Imaging & Studies": {
      "— Essential Imaging": [
        {
          "item": "CT head without contrast",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-",
          "rationale": "Acute change in mental status — rule out stroke, subdural hematoma, hydrocephalus; first-line imaging"
        },
        {
          "item": "Chest X-ray",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-",
          "rationale": "Pneumonia screen (common delirium trigger in elderly PD patients)"
        },
        {
          "item": "ECG (12-lead)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "QTc assessment **before starting pimavanserin** (prolongs QTc); baseline for antipsychotic monitoring"
        }
      ],
      "— Extended Imaging": [
        {
          "item": "MRI brain with/without contrast",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Structural lesion, stroke, NPH, Lewy body pattern atrophy; indicated if new or atypical psychosis, rapid cognitive decline, or focal neurologic signs"
        },
        {
          "item": "EEG (routine or continuous)",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "If concern for nonconvulsive seizures or Creutzfeldt-Jakob disease; periodic discharges in CJD"
        }
      ],
      "— Rare/Specialized Studies": [
        {
          "item": "DaTscan (I-123 ioflupane SPECT)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Only if PD diagnosis is uncertain and DLB vs AD vs PD-D needs clarification; not routinely needed if PD diagnosis established"
        },
        {
          "item": "FDG-PET brain",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Research/atypical cases — posterior cortical hypometabolism supports DLB/PDD"
        },
        {
          "item": "Neuropsychological testing",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Quantify cognitive deficits; distinguish PD-MCI from PDD; track progression; help predict psychosis risk"
        },
        {
          "item": "Polysomnography",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "If RBD evaluation needed or if sleep fragmentation contributing to psychotic symptoms"
        }
      ]
    },
    "Treatment": {
      "— Acute / Emergency Treatment": [
        {
          "item": "Rule out delirium",
          "route": "-",
          "indication": "Identify treatable precipitants of psychosis",
          "dosing": {
            "doseOptions": [
              {
                "text": "-",
                "orderSentence": "Rule out delirium - -"
              }
            ],
            "route": "-",
            "instructions": "UTI, pneumonia, constipation/fecal impaction, medication changes, hospitalization itself — treat the underlying cause; psychosis may resolve entirely",
            "orderSentence": "Rule out delirium - -"
          },
          "contraindications": "-",
          "monitoring": "Vital signs, urinalysis, CBC, CMP, chest X-ray",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Medication review — eliminate offending agents",
          "route": "-",
          "indication": "Deprescribe medications contributing to psychosis",
          "dosing": {
            "doseOptions": [
              {
                "text": "-",
                "orderSentence": "Medication review — eliminate offending agents - -"
              }
            ],
            "route": "-",
            "instructions": "Systematic deprescribing in order of cognitive risk (stop first → stop last): **anticholinergics** (benztropine, trihexyphenidyl) → **amantadine** → **MAO-B inhibitors** (selegiline, rasagiline) → **dopamine agonists** (pramipexole, ropinirole, rotigotine) → **COMT inhibitors** (entacapone) → **reduce levodopa dose** (last resort — maintain motor function)",
            "orderSentence": "Medication review — eliminate offending agents - -"
          },
          "contraindications": "Do not abruptly discontinue dopaminergic agents — risk of neuroleptic malignant-like syndrome",
          "monitoring": "Motor function (UPDRS); symptom re-assessment after each change",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Environmental measures",
          "route": "-",
          "indication": "Non-pharmacologic psychosis management",
          "dosing": {
            "doseOptions": [
              {
                "text": "-",
                "orderSentence": "Environmental measures - -"
              }
            ],
            "route": "-",
            "instructions": "Adequate lighting (reduce visual hallucinations), familiar objects, reorientation, sleep hygiene, minimize polypharmacy",
            "orderSentence": "Environmental measures - -"
          },
          "contraindications": "-",
          "monitoring": "Psychosis symptom frequency; sleep quality",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Quetiapine",
          "route": "PO",
          "indication": "Acute agitation in PDP — first-line; lowest D2 affinity among available agents",
          "dosing": {
            "doseOptions": [
              {
                "text": "12.5-25 mg",
                "orderSentence": "Quetiapine 12.5-25 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "start 12.5 mg, may repeat in 2 hours",
            "orderSentence": "Quetiapine 12.5-25 mg PO"
          },
          "contraindications": "Avoid IM formulation; avoid if QTc >500 ms",
          "monitoring": "Sedation level; QTc; metabolic panel; glucose",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Lorazepam",
          "route": "PO/IV/IM",
          "indication": "Severe agitation in PDP — benzodiazepine safer than typical antipsychotic",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5-1 mg",
                "orderSentence": "Lorazepam 0.5-1 mg PO/IV/IM"
              }
            ],
            "route": "PO/IV/IM",
            "instructions": "use lowest effective dose",
            "orderSentence": "Lorazepam 0.5-1 mg PO/IV/IM"
          },
          "contraindications": "Respiratory depression; avoid in severe hepatic impairment",
          "monitoring": "Sedation level; respiratory rate; fall risk",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "— First-Line Chronic Treatment": [
        {
          "item": "Pimavanserin (Nuplazid)",
          "route": "PO",
          "indication": "PDP — only FDA-approved medication (2016); selective 5-HT2A inverse agonist; no D2 blockade",
          "dosing": {
            "doseOptions": [
              {
                "text": "34 mg",
                "orderSentence": "Pimavanserin (Nuplazid) 34 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "no titration needed; onset of effect 4-6 weeks",
            "orderSentence": "Pimavanserin (Nuplazid) 34 mg PO"
          },
          "contraindications": "Avoid if QTc >500 ms; avoid with strong CYP3A4 inhibitors",
          "monitoring": "Baseline ECG and periodic QTc monitoring; no dose adjustment in renal impairment; prior authorization usually required",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Quetiapine (chronic)",
          "route": "PO",
          "indication": "PDP — best-studied alternative to pimavanserin; very low D2 affinity at low doses",
          "dosing": {
            "doseOptions": [
              {
                "text": "12.5-150 mg",
                "orderSentence": "Quetiapine (chronic) 12.5-150 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "start 12.5 mg, titrate by 12.5-25 mg every 3-5 days; target lowest effective dose; typical effective range 25-100 mg qhs",
            "orderSentence": "Quetiapine (chronic) 12.5-150 mg PO"
          },
          "contraindications": "Orthostatic hypotension risk (already a PD issue)",
          "monitoring": "Metabolic panel; fasting glucose and lipids; weight; orthostatic blood pressure",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "— Second-Line Treatment": [
        {
          "item": "Clozapine",
          "route": "PO",
          "indication": "PDP — best evidence for efficacy (Level B, AAN); low D2 affinity; effective at very low doses",
          "dosing": {
            "doseOptions": [
              {
                "text": "6.25-50 mg",
                "orderSentence": "Clozapine 6.25-50 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "start 6.25 mg (1/4 of 25 mg tablet), titrate by 6.25 mg every 3-7 days; target 12.5-50 mg/day",
            "orderSentence": "Clozapine 6.25-50 mg PO"
          },
          "contraindications": "Requires REMS program enrollment; contraindicated if unable to comply with ANC monitoring; risk of agranulocytosis (~1%); risk of myocarditis (rare)",
          "monitoring": "Mandatory ANC monitoring (weekly x6 months, then biweekly x6 months, then monthly); metabolic panel; fasting glucose and lipids; weight",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Rivastigmine",
          "route": "PO/transdermal",
          "indication": "PD dementia with psychosis — addresses cholinergic deficit; may reduce hallucinations (EXPRESS trial)",
          "dosing": {
            "doseOptions": [
              {
                "text": "Rivastigmine",
                "orderSentence": "Rivastigmine Rivastigmine 1.5 mg"
              }
            ],
            "route": "1.5 mg",
            "instructions": "BID",
            "orderSentence": "Rivastigmine Rivastigmine 1.5 mg"
          },
          "contraindications": "GI side effects common with oral; tremor may transiently worsen",
          "monitoring": "GI tolerability; cognitive testing (MMSE/MoCA); tremor severity",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "— Refractory Psychosis Management": [
        {
          "item": "Combination therapy (pimavanserin + quetiapine or + clozapine)",
          "route": "PO",
          "indication": "Severe refractory PDP — limited evidence but used in practice",
          "dosing": {
            "doseOptions": [
              {
                "text": "-",
                "orderSentence": "Combination therapy (pimavanserin + quetiapine or + clozapine) - -"
              }
            ],
            "route": "-",
            "instructions": "Use pimavanserin + quetiapine (or + clozapine) per individual dosing guidelines above",
            "orderSentence": "Combination therapy (pimavanserin + quetiapine or + clozapine) - -"
          },
          "contraindications": "Additive QTc prolongation risk with pimavanserin + quetiapine; additive sedation",
          "monitoring": "QTc (combined agents); ANC if clozapine included; metabolic panel; sedation level",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Electroconvulsive therapy (ECT)",
          "route": "-",
          "indication": "Severe PDP refractory to all medications; also improves motor symptoms temporarily",
          "dosing": {
            "doseOptions": [
              {
                "text": "-",
                "orderSentence": "Electroconvulsive therapy (ECT) - -"
              }
            ],
            "route": "-",
            "instructions": "Case reports/small series show benefit; logistic and access barriers",
            "orderSentence": "Electroconvulsive therapy (ECT) - -"
          },
          "contraindications": "Standard ECT contraindications (raised ICP, pheochromocytoma, unstable aneurysm)",
          "monitoring": "Post-procedure cognitive assessment; motor function (UPDRS); seizure duration",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Reduce levodopa",
          "route": "PO",
          "indication": "Refractory psychosis — last resort; accept some motor worsening to control psychosis",
          "dosing": {
            "doseOptions": [
              {
                "text": "-",
                "orderSentence": "Reduce levodopa - PO"
              }
            ],
            "route": "PO",
            "instructions": "If all else fails, gradually reduce levodopa; family discussion about trade-offs essential",
            "orderSentence": "Reduce levodopa - PO"
          },
          "contraindications": "Never abruptly discontinue — risk of neuroleptic malignant-like syndrome",
          "monitoring": "Motor function (UPDRS); psychosis severity; ADL function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Structured care environment",
          "route": "-",
          "indication": "Persistent and dangerous psychosis unresponsive to treatment",
          "dosing": {
            "doseOptions": [
              {
                "text": "-",
                "orderSentence": "Structured care environment - -"
              }
            ],
            "route": "-",
            "instructions": "Consider memory care or psychiatric facility with movement disorder expertise",
            "orderSentence": "Structured care environment - -"
          },
          "contraindications": "-",
          "monitoring": "Safety assessments; psychosis severity; caregiver burden",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "— Referrals": [
        {
          "rationale": "PDP medication optimization — balance motor and psychiatric symptoms; pimavanserin initiation; clozapine program enrollment"
        },
        {
          "rationale": "Severe psychosis, medication-refractory symptoms, ECT evaluation, capacity assessment"
        },
        {
          "rationale": "Cognitive testing — PD-MCI vs PDD staging; psychosis risk stratification; capacity evaluation"
        },
        {
          "rationale": "Caregiver support, home safety evaluation, placement assistance if needed"
        },
        {
          "rationale": "Goals of care discussion if advanced PDD with refractory psychosis — quality of life focus"
        }
      ]
    }
  }
}